Results overview: Found 2 records in 0.01 seconds.
Articles, 2 records found
Articles 2 records found  
1.
15 p, 949.7 KB An update on the use of tolvaptan for autosomal dominant polycystic kidney disease : Consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International / Müller, Roman-Ulrich U. (Cecad. University of Cologne. Faculty of Medicine and University Hospital Cologne) ; Messchendorp, A. Lianne (Department of Nephrology. University Medical Center Groningen. University of Groningen) ; Birn, Henrik (Departments of Clinical Medicine and Biomedicine. Aarhus University) ; Capasso, Giovambattista (Biogem Institute for Molecular Biology and Genetics) ; Cornec-Le Gall, Emilie (University Brest. Inserm. Umr 1078. GGB. Chu Brest) ; Devuyst, Olivier (Division of Nephrology. Ucl Medical School) ; Van Eerde, Albertien (Department of Genetics. University Medical Center Utrecht) ; Guirchoun, Patrick (Association PolyKystose France (PKD France)) ; Harris, Tess (Pkd International) ; Hoorn, Ewout J. (University Medical Center Rotterdam) ; Knoers, Nine V.A.M. (Department Genetics. University Medical Centre Groningen) ; Korst, Uwe (Pkd Familiäre Zystennieren E.V.) ; Mekahli, Djalila (Department of Pediatric Nephrology and Organ Transplantation. University Hospitals Leuven) ; Le Meur, Yannick (Department of Nephrology. Hemodialysis and Renal Transplantation. Chu and University of Brest) ; Nijenhuis, Tom (Radboud University Medical Center) ; Ong, Albert C.M. (Sheffield Kidney Institute. Sheffield Teaching Hospitals Nhs Foundation Trust) ; Sayer, John A. (Translational and Clinical Research Institute. Faculty of Medical Sciences. Newcastle University) ; Schaefer, Franz (Division of Pediatric Nephrology. Center for Pediatrics and Adolescent Medicine. Heidelberg University Hospital) ; Servais, Aaude (Nephrology and Transplantation Department. Necker University Hospital. Aphp) ; Tesar, Vladimir (Department of Nephrology. 1st Faculty of Medicine. General University Hospital) ; Torra Balcells, Roser (Institut d'Investigació Biomèdica Sant Pau) ; Walsh, Stephen B. (Department of Renal Medicine. University College London) ; Gansevoort, Roon T. (Department of Nephrology. University Medical Center Groningen. University of Groningen) ; Universitat Autònoma de Barcelona
Approval of the vasopressin V2 receptor antagonist tolvaptan-based on the landmark TEMPO 3:4 trial-marked a transformation in the management of autosomal dominant polycystic kidney disease (ADPKD). This development has advanced patient care in ADPKD from general measures to prevent progression of chronic kidney disease to targeting disease-specific mechanisms. [...]
2022 - 10.1093/ndt/gfab312
Nephrology Dialysis Transplantation, Vol. 37 Núm. 5 (january 2022) , p. 825-839  
2.
12 p, 666.2 KB Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease : a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice / Gansevoort, Ron T.. (University Medical Center Groningen, University of Groningen) ; Arici, Mustafa (Hacettepe University Faculty of Medicine) ; Benzing, Thomas (University of Cologne) ; Birn, Henrik (Aarhus University) ; Capasso, Giovambattista (Second University of Naples) ; Covic, Adrian (and 'Grigore T. Popa' University of Medicine. C.I. PARHON' University Hospital) ; Devuyst, Olivier (UCL Medical School) ; Drechsler, Christiane (University Hospital. University of Würzburg) ; Eckardt, Kai-Uwe (Friedrich-Alexander University Erlangen-Nürnberg (FAU)) ; Emma, Francesco (Bambino Gesù Children's Hospital) ; Knebelmann, Bertrand (Paris Descartes University. Hôpital Necker) ; Le Meur, Yannick (Hôpital La Cavale Blanche, Centre Hospitalier Régional Universitaire de Brest) ; Massy, Ziad A. (University of Paris Saclay and Paris Ouest-Versailles-Saint-Quentin-en-Yvelines (UVSQ)) ; Ong, Albert C. M. (University of Sheffield Medical School) ; Ortiz, Alberto (Red de Investigación Renal) ; Schaefer, Franz (Heidelberg University Hospital (Alemanya)) ; Torra Balcells, Roser (Institut d'Investigació Biomèdica Sant Pau) ; Vanholder, Raymond (Universitair Ziekenhuis Gent) ; Więcek, Andrzej (Medical University of Silesia in Katowice) ; Zoccali, Carmine (CNR-IFC Clinical Epidemiology and Pathophysiology of Renal Diseases and Hypertension Unit, Reggio Calabria c/o Ospedali Riuniti) ; Van Biesen, Wim (Universitair Ziekenhuis Gent) ; Universitat Autònoma de Barcelona ; Institut Puigvert
Recently, the European Medicines Agency approved the use of the vasopressin V2 receptor antagonist tolvaptan to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adult patients with chronic kidney disease stages 1-3 at initiation of treatment with evidence of rapidly progressing disease. [...]
2016 - 10.1093/ndt/gfv456
Nephrology Dialysis Transplantation, Vol. 31 (january 2016) , p. 337-348  

See also: similar author names
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.